When depression has not improved with standard medications, the decision between Spravato versus ECT depression treatment can feel urgent and deeply personal. Both options are used for serious, treatment-resistant depression, but they differ in how they work, how quickly they may help, the commitment involved, and the side effects patients may need to weigh. The right choice is not simply the newest treatment or the most intensive one. It is the treatment that fits the severity of symptoms, medical history, safety needs, preferences, and the support available around the patient.
For someone who has spent months or years trying to feel better, a thoughtful conversation about advanced depression care can be a meaningful next step.
What Spravato Is and Who It May Help
Spravato is the brand name for esketamine, a nasal spray medication derived from ketamine. It is FDA-approved for adults with treatment-resistant depression and, in certain circumstances, depressive symptoms associated with major depressive disorder with acute suicidal ideation or behavior. It is used alongside an oral antidepressant rather than as a stand-alone treatment.
Unlike many conventional antidepressants, which primarily affect serotonin, norepinephrine, or dopamine pathways, esketamine acts on the brain’s glutamate system. This pathway is involved in learning, neuroplasticity, and mood regulation. Some patients experience improvement more quickly than they have with traditional antidepressants, although response varies substantially from person to person.
Spravato is administered in a certified clinical setting under a federal safety program called REMS. Patients self-administer the nasal spray while a trained team monitors them for at least two hours afterward. Temporary dissociation, dizziness, sedation, nausea, increased blood pressure, and altered perception can occur. Because driving and operating machinery are not permitted until the next day after a restful night’s sleep, patients need reliable transportation home.
Treatment usually begins with twice-weekly visits, then may taper to weekly or every-other-week maintenance visits based on symptom response and the prescriber’s plan. For patients who value a non-surgical option and can attend monitored appointments, this schedule may be manageable. For others, frequent clinic visits can be a practical barrier.
What ECT Is and Why It Remains a Valuable Option
Electroconvulsive therapy, or ECT, is a medical treatment performed under general anesthesia. A carefully controlled electrical stimulus produces a brief seizure in the brain. Although the procedure is often misunderstood because of outdated media portrayals, modern ECT is delivered in a highly monitored medical environment with anesthesia, muscle relaxation, and individualized electrode placement.
ECT has a long history of effectiveness for severe depression, particularly when symptoms are life-threatening, profoundly disabling, psychotic, or resistant to multiple previous treatments. It may also be considered when a person is unable to eat, drink, sleep, or function because of depression, or when a rapid response is needed due to high suicide risk. It can be especially important when waiting weeks for a medication response is not clinically appropriate.
An acute course of ECT commonly involves treatments several times per week for a number of weeks. Many patients then need continuation treatment, which may include medication, psychotherapy, maintenance ECT, or another carefully designed plan to reduce relapse risk.
The most discussed trade-off with ECT is memory. Some people experience short-term confusion after treatment, difficulty remembering events around the treatment period, or gaps in autobiographical memory. Memory effects vary by person and may improve over time, but they deserve an honest discussion before treatment begins. ECT also requires anesthesia and medical clearance, which can make it less suitable for some patients depending on their health status.
Spravato Versus ECT Depression Treatment: The Key Differences
Spravato and ECT are not interchangeable versions of the same intervention. They may both be considered after standard depression treatments have not provided enough relief, but their clinical roles can look very different.
ECT generally has the stronger track record when depression is severe, urgent, psychotic, catatonic, or accompanied by an immediate safety concern. It is often viewed as one of the most effective treatments available for major depressive episodes of this intensity. Its potential for a faster, substantial response is a central reason physicians may recommend it in a hospital or psychiatric setting.
Spravato may be a more appropriate consideration for adults with treatment-resistant depression who are stable enough for scheduled outpatient care and who prefer to avoid anesthesia and an induced seizure. Some patients find its monitored, office-based model less intimidating than ECT. Others may find the twice-weekly starting schedule and required observation period difficult to fit around work, caregiving, or travel.
The side-effect profiles are also different. Spravato commonly causes temporary changes in perception or awareness during the visit, while ECT may involve headache, muscle soreness, short-term confusion, and memory concerns. Neither option should be chosen based on convenience alone. A clinician should review cardiovascular health, substance use history, other medications, psychiatric diagnoses, prior treatment response, and the practical realities of aftercare.
Questions That Help Clarify the Decision
A productive evaluation starts by looking beyond the diagnosis of depression. “Treatment-resistant” can mean different things. A person may have tried several medications but never had adequate dose, duration, adherence support, psychotherapy, or a full reassessment of contributing medical and emotional factors. In other cases, the treatment history is extensive and symptoms remain severe despite excellent care.
Ask how urgent symptom relief needs to be. Are there thoughts of self-harm, psychosis, inability to care for basic needs, or a rapid decline in functioning? If so, ECT or a higher level of psychiatric care may be more appropriate than an outpatient treatment pathway. Anyone in immediate danger should call 911, go to the nearest emergency department, or call or text 988 for the Suicide & Crisis Lifeline.
It also helps to ask what has happened with previous treatments. Did antidepressants cause intolerable side effects? Did they help somewhat but not enough? Has the person responded to ketamine treatment in the past? Are memory concerns particularly significant because of work, school, or caregiving responsibilities? These answers shape the risk-benefit discussion.
Medical considerations matter as well. Spravato can temporarily raise blood pressure and may not be appropriate for people with certain vascular conditions. ECT involves anesthesia, so a thorough medical review is necessary. Pregnancy, bipolar disorder, substance use concerns, seizure history, and co-occurring conditions all call for individualized planning rather than a one-size-fits-all recommendation.
The Role of Ongoing Support
Neither Spravato nor ECT is a complete plan by itself. Depression frequently requires continuing care after symptoms improve. That can include medication management, therapy, sleep and stress support, treatment for chronic pain or trauma, healthy routines, and regular monitoring for relapse.
For some patients, the most valuable change is finally having a care team that listens closely to the full pattern of symptoms instead of viewing depression as a medication checklist. At Quad Cities Ketamine Clinic, individualized treatment conversations can help patients understand whether monitored ketamine-based care may fit their history and goals, while also recognizing when another level or type of psychiatric treatment is needed.
Cost and access should be discussed early, too. Spravato may have insurance coverage when specific criteria are met, though prior authorization and plan rules can affect access. ECT is often covered when medically necessary, but coverage, facility availability, transportation, time away from work, and caregiver support can still influence what is realistic. A treatment recommendation only helps if a patient can safely follow through with it.
Choosing With Clarity, Not Pressure
The question is not whether Spravato or ECT is “better” in every circumstance. ECT may offer a critical path forward for severe or urgent depression, while Spravato may provide an outpatient option for appropriate patients who need a different approach after conventional treatment has fallen short. Both require professional oversight, informed consent, and a plan for what comes next.
If depression is taking away your ability to work, connect, rest, or recognize yourself, you do not have to decide alone. A comprehensive psychiatric evaluation can turn a frightening choice into a clearer, medically grounded plan for relief and recovery.
